Variability of Serum CYFRA 21 - 1 and Its Susceptibility to Clinical Characteristics in Individuals Without Cancer: a 4-year Retrospective Analysis

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2023 Sep 13

PMID 37705035

Authors

Asami Minamibata

Yoshihito Kono

Taichiro Arimoto

Yoshinori Marunaka

Koichi Takayama

Affiliations

Soon will be listed here.

Abstract

Background: CYFRA 21 - 1 is a useful marker for diagnosing and monitoring lung cancer. However, its stability remains unclear. Moreover, while its applicability to screening is now being investigated, CYFRA 21 - 1 levels in individuals without cancer, who are targets for cancer screening, have not yet been the focus of research. Therefore, the present study investigated variability in and the factors increasing serum CYFRA 21 - 1 levels.

Methods: This retrospective study recruited 951 individuals undergoing annual medical examinations for six years. We used data obtained in the first four years. Variability in serum CYFRA 21 - 1 levels over a period of four years were investigated. CYFRA 21 - 1 was categorized as normal (≤ 3.5 ng/ml) or elevated (> 3.5 ng/ml). The rate of an elevated level in one visit and the transition from an elevated to normal level between visits were visualized. A multiple logistic regression model was used to study the relationships between the frequency of elevated CYFRA 21 - 1 levels and clinical characteristics, such as age, sex, body mass index, weight changes, and the smoking status.

Results: Approximately 5% of subjects had elevated CYFRA 21 - 1 levels once in five tests over four years, while 15% had elevated CYFRA 21 - 1 levels once or more. Among subjects with elevated CYFRA 21 - 1 levels in one blood test, between 63 and 72% had normal levels in the next test. The median CYFRA 21 - 1 level in subjects with elevations in one blood test significantly decreased in the next test at all four time points. The frequency of elevated CYFRA 21 - 1 levels was associated with an older age [odds ratio (OR) = 6.99, 95% confidence interval (CI) = 3.01-16.2], current heavy smoking (OR = 3.46, 95% CI = 1.52-7.9), and weight loss (OR = 1.86, 95% CI = 1.07-3.24).

Conclusions: Variability in and the factors increasing serum CYFRA 21 - 1 levels beyond the cut-off value need to be considered when interpretating CYFRA 21 - 1 test results. The future application of CYFRA 21 - 1 to lung cancer screening may require more than a single measurement.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Toivola D, Strnad P, Habtezion A, Omary M . Intermediate filaments take the heat as stress proteins. Trends Cell Biol. 2010; 20(2):79-91. PMC: 2843093. DOI: 10.1016/j.tcb.2009.11.004. View

Geisler F, Leube R . Epithelial Intermediate Filaments: Guardians against Microbial Infection?. Cells. 2016; 5(3). PMC: 5040971. DOI: 10.3390/cells5030029. View

Sharma P, Alizadeh J, Juarez M, Samali A, Halayko A, Kenyon N . Autophagy, Apoptosis, the Unfolded Protein Response, and Lung Function in Idiopathic Pulmonary Fibrosis. Cells. 2021; 10(7). PMC: 8307368. DOI: 10.3390/cells10071642. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Abtahi S, Malekzadeh M, Nikravan G, Ghaderi A . Measurement of Lung Cancer Tumor Markers in a Glass Wool Company Workers Exposed to Respirable Synthetic Vitreous Fiber and Dust. Int J Occup Environ Med. 2018; 9(1):23-31. PMC: 6466973. DOI: 10.15171/ijoem.2018.1147. View

de Koning H, van der Aalst C, de Jong P, Scholten E, Nackaerts K, Heuvelmans M . Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382(6):503-513. DOI: 10.1056/NEJMoa1911793. View

Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H . CYFRA 21-1. A new marker in lung cancer. Cancer. 1993; 72(3):707-13. DOI: 10.1002/1097-0142(19930801)72:3<707::aid-cncr2820720313>3.0.co;2-x. View

Karantza V . Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2010; 30(2):127-38. PMC: 3155291. DOI: 10.1038/onc.2010.456. View

10.

Molyneaux P, Fahy W, Byrne A, Braybrooke R, Saunders P, Toshner R . CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. Am J Respir Crit Care Med. 2022; 205(12):1440-1448. PMC: 9875897. DOI: 10.1164/rccm.202107-1769OC. View

11.

Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N . Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg. 2007; 32(3):435-9. DOI: 10.1016/j.ejcts.2007.05.014. View

12.

Yang Y, Xu M, Huang H, Jiang X, Gong K, Liu Y . Serum carcinoembryonic antigen elevation in benign lung diseases. Sci Rep. 2021; 11(1):19044. PMC: 8463604. DOI: 10.1038/s41598-021-98513-8. View

13.

Matsutani T, Kang S, Miyashita M, Sasajima K, Choudhry M, Bland K . Young and middle-age associated differences in cytokeratin expression after bone fracture, tissue trauma, and hemorrhage. Am J Surg. 2006; 193(1):61-8. DOI: 10.1016/j.amjsurg.2006.07.012. View

14.

Gonzalez-Blanco L, Bermudez M, Bermejo-Millo J, Gutierrez-Rodriguez J, Solano J, Antuna E . Cell interactome in sarcopenia during aging. J Cachexia Sarcopenia Muscle. 2022; 13(2):919-931. PMC: 8977965. DOI: 10.1002/jcsm.12937. View

15.

Cipollina C, Bruno A, Fasola S, Cristaldi M, Patella B, Inguanta R . Cellular and Molecular Signatures of Oxidative Stress in Bronchial Epithelial Cell Models Injured by Cigarette Smoke Extract. Int J Mol Sci. 2022; 23(3). PMC: 8836577. DOI: 10.3390/ijms23031770. View

16.

Phan T, Paliogiannis P, Nasrallah G, Giordo R, Eid A, Fois A . Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci. 2020; 78(5):2031-2057. PMC: 7669490. DOI: 10.1007/s00018-020-03693-7. View

17.

Koo T, Li M . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2):155-63. PMC: 4913118. DOI: 10.1016/j.jcm.2016.02.012. View

18.

Molina R, Marrades R, Auge J, Escudero J, Vinolas N, Reguart N . Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. Am J Respir Crit Care Med. 2015; 193(4):427-37. DOI: 10.1164/rccm.201404-0603OC. View

19.

Guida F, Sun N, Bantis L, Muller D, Li P, Taguchi A . Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol. 2018; 4(10):e182078. PMC: 6233784. DOI: 10.1001/jamaoncol.2018.2078. View

20.

Blanco-Prieto S, De Chiara L, Rodriguez-Girondo M, Vazquez-Iglesias L, Rodriguez-Berrocal F, Fernandez-Villar A . Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units. Sci Rep. 2017; 7:41151. PMC: 5259733. DOI: 10.1038/srep41151. View